0001209191-21-004458.txt : 20210120
0001209191-21-004458.hdr.sgml : 20210120
20210120180727
ACCESSION NUMBER: 0001209191-21-004458
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210115
FILED AS OF DATE: 20210120
DATE AS OF CHANGE: 20210120
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Klein Lawrence Otto
CENTRAL INDEX KEY: 0001762583
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37923
FILM NUMBER: 21539818
MAIL ADDRESS:
STREET 1: C/O CRISPR THERAPEUTICS AG
STREET 2: 610 MAIN STREET 7TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CRISPR Therapeutics AG
CENTRAL INDEX KEY: 0001674416
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 473173478
STATE OF INCORPORATION: V8
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: BAARERSTRASSE 14
CITY: ZUG
STATE: V8
ZIP: CH-6300
BUSINESS PHONE: 6173154600
MAIL ADDRESS:
STREET 1: BAARERSTRASSE 14
CITY: ZUG
STATE: V8
ZIP: CH-6300
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-01-15
0
0001674416
CRISPR Therapeutics AG
CRSP
0001762583
Klein Lawrence Otto
C/O CRISPR THERAPEUTICS, INC.
610 MAIN STREET
CAMBRIDGE
MA
02139
0
1
0
0
CBO & COO
Common Shares
2021-01-15
4
M
0
8666
12.57
A
28666
D
Common Shares
2021-01-15
4
S
0
2911
211.44
D
25755
D
Common Shares
2021-01-15
4
S
0
2555
212.54
D
23200
D
Common Shares
2021-01-15
4
S
0
1200
213.71
D
22000
D
Common Shares
2021-01-15
4
S
0
1400
214.46
D
20600
D
Common Shares
2021-01-15
4
S
0
400
216.24
D
20200
D
Common Shares
2021-01-15
4
S
0
200
217.45
D
20000
D
Common Shares
2021-01-15
4
M
0
16344
14.43
A
36334
D
Common Shares
2021-01-15
4
S
0
634
212.20
D
35700
D
Common Shares
2021-01-15
4
S
0
2800
213.64
D
32900
D
Common Shares
2021-01-15
4
S
0
700
214.60
D
32200
D
Common Shares
2021-01-15
4
S
0
1500
216.39
D
30700
D
Common Shares
2021-01-15
4
S
0
9997
217.42
D
20703
D
Common Shares
2021-01-15
4
S
0
701
218.54
D
20002
D
Common Shares
2021-01-15
4
S
0
2
219.99
D
20000
D
Stock Option (Right to Buy)
12.57
2021-01-15
4
M
0
8666
0.00
D
2026-07-14
Common Shares
8666
0
D
Stock Option (Right to Buy)
14.43
2021-01-15
4
M
0
16334
0.00
D
2027-06-14
Common Shares
16334
14666
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $211.01 to $212.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $212.01 to $212.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $213.10 to $214.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $214.125 to $214.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $216.15 to $216.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $217.42 to $217.47, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $212.01 to $212.79, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $213.48 to $214.31, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $214.60 to $214.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $216.00 to $216.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $217.22 to $217.93, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $218.25 to $218.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $219.99 to $219.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
100% of the shares shall vest in 48 equal monthly installments on the thirty-first day of each month, with the first vesting event on October 31, 2016.
100% of the shares shall vest in 48 equal monthly installments on the fifteenth day of each month, with the first vesting event on July 15, 2017.
/s/ Michael Esposito, attorney-in-fact
2021-01-20